Ganfort Eye Drops

Pays: Singapour

Langue: anglais

Source: HSA (Health Sciences Authority)

Ingrédients actifs:

Bimatoprost; Timolol maleate 6.8mg/ml eqv. to Timolol base

Disponible depuis:

ABBVIE PTE. LTD.

Code ATC:

S01ED51

Dosage:

0.3mg/ml

forme pharmaceutique:

SOLUTION, STERILE

Composition:

Bimatoprost 0.3mg/ml; Timolol maleate 6.8mg/ml eqv. to Timolol base 5mg/ml

Mode d'administration:

OPHTHALMIC

Type d'ordonnance:

Prescription Only

Fabriqué par:

Allergan Pharmaceuticals Ireland

Statut de autorisation:

ACTIVE

Date de l'autorisation:

2008-12-29

Notice patient

 
GANFORT™

eye drops, solution 
Bimatoprost 0.3 mg/mL and timolol 5.0 mg/mL 

DESCRIPTION 
Each mL contains: 0.3 mg bimatoprost and 5
mg timolol equivalent to 6.8 mg of timolol maleate, 
benzalkonium chloride as preservative, sodium chloride,
dibasic sodium phosphate heptahydrate, citric 
acid monohydrate, hydrochloric acid or sodium hydroxide
(to adjust pH), purified water. 

CLINICAL PHARMACOLOGY 
PHARMACODYNAMIC PROPERTIES 
_Pharmacotherapeutic group: _
Ophthalmological – beta-blocking
agents – timolol, combinations_ _
ATC code: SO1ED 51 
_Mechanism of action: _
GANFORT™ consists of two active substances: bimatoprost and
timolol maleate. These two components 
decrease elevated intraocular pressure (IOP) by
complementary mechanisms of action and the 
combined effect results in additional IOP reduction compared
to either compound administered alone. 
GANFORT™ has a rapid onset of action. 
Bimatoprost is a potent ocular hypotensive agent, which selectively
mimics the effects of naturally 
occuring  prostamide F
2α
. It is structurally related to prostaglandin F
2α
 (PGF
2α
), except that it is 
electrochemically neutral by virtue of the ethanolamide group
at position C1. It is pharmacologically 
unique and acts through an identified prostamide receptor.
The prostamide receptor has been 
structurally identified as a heterodimer of an alternative mRNA
splicing variant of the prostanoid FP 
receptor (alt.FP4 ) and the FP wild type. 
The efficacy of bimatoprost may be related to a
dual mechanism of action on aqueous humour outflow 
that involves both the uveoscleral and the trabecular
meshwork/Schlemm’s canal pathways.  Studies in 
living human subjects, human eyes in organ culture, and
studies on human ciliary smooth muscle cells, 
trabecular meshwork cells, and endothelial cells of Schlemm's
canal all indicate that bimatoprost 
stimulates both trab

Résumé des caractéristiques du produit

GANFORT®
eye drops, solution
Bimatoprost 0.3 mg/mL and timolol 5.0 mg/mL
DESCRIPTION
Each mL contains: 0.3 mg bimatoprost and 5 mg timolol equivalent to
6.8 mg of timolol maleate,
benzalkonium chloride as preservative, sodium chloride, dibasic sodium
phosphate heptahydrate, citric
acid monohydrate, hydrochloric acid or sodium hydroxide (to adjust
pH), purified water.
CLINICAL PHARMACOLOGY
PHARMACODYNAMIC PROPERTIES
_Pharmacotherapeutic group:_
Ophthalmological – beta-blocking agents – timolol, combinations
ATC code: SO1ED 51
_Mechanism of action:_
GANFORT® consists of two active substances: bimatoprost and timolol
maleate. These two components
decrease elevated intraocular pressure (IOP) by complementary
mechanisms of action and the combined
effect results in additional IOP reduction compared to either compound
administered alone. GANFORT®
has a rapid onset of action.
Bimatoprost is a potent ocular hypotensive agent, which selectively
mimics the effects of naturally
occuring prostamide F
2α
. It is structurally related to prostaglandin F
2α
(PGF
2α
), except that it is
electrochemically neutral by virtue of the ethanolamide group at
position C1. It is pharmacologically
unique and acts through an identified prostamide receptor. The
prostamide receptor has been
structurally identified as a heterodimer of an alternative mRNA
splicing variant of the prostanoid FP
receptor (alt.FP4 ) and the FP wild type.
The efficacy of bimatoprost may be related to a dual mechanism of
action on aqueous humour outflow
that involves both the uveoscleral and the trabecular
meshwork/Schlemm’s canal pathways. Studies in
living human subjects, human eyes in organ culture, and studies on
human ciliary smooth muscle cells,
trabecular meshwork cells, and endothelial cells of Schlemm's canal
all indicate that bimatoprost
stimulates both trabecular and uveoscleral outflow pathways.
Timolol is a beta
1
and beta
2
non-selective adrenergic receptor blocking agent that does not have
significant intrinsic sympathomimetic, direct myocard